Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -7.97
- Piotroski Score 3.00
- Grade Overweight
- Symbol (RAPT)
- Company RAPT Therapeutics, Inc.
- Price $1.08
- Changes Percentage (2.38%)
- Change $0.03
- Day Low $1.04
- Day High $1.12
- Year High $27.35
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/05/2025
- Fiscal Year End N/A
- Average Stock Price Target $33.00
- High Stock Price Target $55.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.08
- Trailing P/E Ratio -1.25
- Forward P/E Ratio -1.25
- P/E Growth -1.25
- Net Income $-116,798,000
Income Statement
Quarterly
Annual
Latest News of RAPT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
With Scottie Barnes back, let the experiments begin for the Toronto Raptors
The Toronto Raptors are showing positive signs in a rebuilding season, with players like Gradey Dick, RJ Barrett, and Jakob Poeltl stepping up. Scottie Barnes returned from injury with an impactful pe...
By The New York Times | 16 hours ago -
Barrett scores 31, Barnes adds 17 in return from injury, and Raptors beat Timberwolves 110-105
RJ Barrett led the Toronto Raptors to a 110-105 victory over the Minnesota Timberwolves with 31 points. Scottie Barnes returned from injury with 17 points. The Raptors secured their first back-to-back...
By AP NEWS | 17 hours ago -
Barnes returns to Raptors lineup vs. Timberwolves | Globalnews.ca
Barnes returned to the Toronto Raptors' starting lineup earlier than expected after recovering from a right orbital bone injury. The 23-year-old forward was averaging impressive stats before the injur...
By Global News | 22 hours ago
